Galena Biopharma (SLS) Getting Somewhat Positive Media Coverage, Analysis Shows

Share on StockTwits

News stories about Galena Biopharma (NYSE:SLS) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Galena Biopharma earned a news impact score of 0.17 on Accern’s scale. Accern also gave media coverage about the company an impact score of 46.8336931395566 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Shares of NYSE:SLS traded down $0.04 during trading on Friday, reaching $0.89. The stock had a trading volume of 221,183 shares, compared to its average volume of 471,701. Galena Biopharma has a 52 week low of $0.88 and a 52 week high of $13.47.

Galena Biopharma (NYSE:SLS) last posted its quarterly earnings data on Tuesday, May 15th. The company reported ($1.47) EPS for the quarter.

About Galena Biopharma

Develop biopharmaceuticals

Further Reading: Penny Stocks

Insider Buying and Selling by Quarter for Galena Biopharma (NYSE:SLS)

Receive News & Ratings for Galena Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galena Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply